目的 研究替吉奥联合改良XELOX方案治疗晚期胃癌患者的效果。方法 选择2015年1月-2017年12月韩城市人民医院收治的62例晚期胃癌患者，随机分为两组。对照组采用改良XELOX方案治疗，观察组采用替吉奥联合改良XELOX方案治疗。比较两组的近期疗效，不良反应分级情况以及肿瘤进展时间。结果 观察组的近期有效率为58.06%，明显高于对照组的38.71%（P<0.05）。治疗后，两组的周围神经毒性、白细胞减少、疲劳、肌肉关节疼痛、中性粒细胞减少、呕吐/恶心、贫血、口腔黏膜炎、血小板减少、肾损伤和腹泻等不良反应分级情况相比无明显的差异。观察组和对照组的肿瘤进展时间分别为（6.34±1.27）d和（5.73±1.62）d，两组比较差异无统计学意义。结论 替吉奥胶囊联合改良XELOX方案能显著提高晚期胃癌患者的近期疗效，且不会使不良反应增加，也不会明显影响肿瘤进展时间。

Objective To investigate the effect of S-1 Capsules combined with modified XELOX regimen in treatment of advanced gastric cancer. Methods Selected 62 cases of patients with advanced gastric cancer who were treated in Hancheng People's Hospital from January 2015 to December 2017, divided into two groups randomly. The control group was treated with modified XELOX regimen, while the observation group was treated with modified XELOX regimen combined with Tegafur,Gimeracil and Oteracil Potassium Capsules. The short-term curative effect, grade of adverse reactions and the time of tumor progression were compared between two groups. Results The effective rate of the observation group (58.06%) was significantly higher than control group (38.71%) (P<0.05). There was no significant difference between the two groups in the classification of peripheral nerve toxicity, leukopenia, fatigue, muscle and joint pain, neutropenia, vomiting/nausea, anemia, oral mucositis, thrombocytopenia, renal injury and diarrhea. The time of tumor progression in observation group and control group were (6.34±1.27) d and (5.73 ±1.62) d, there was no significant difference between two groups. Conclusion Tegafur,Gimeracil and Oteracil Potassium Capsules combined with modified XELOX regimen can significantly improve the short-term efficacy of patients with advanced gastric cancer, and will not increase adverse reactions, will not significantly affect the time of tumor progression.